Press Release | Impact of a psycho-educational team in early breast cancer patients’ coping strategies


Cancer is a psychologically traumatic experience for affected individuals. Chemotherpautic medications can also be painful to the same patients. Researchers at Fondazione Poliambulanza, Brescia, Italy conducted a psycho-educational study on early stage breast cancer patients. The main objective of the study was to help women to cope with the physical emotional, and lifestyle changes after the diagnosis of breast cancer by evaluating the effect of group action on the participating women. A total of 97 women, participated in the study and were grouped into in 13 psycho-educational groups. All the groups consisted of female patients suffering from breast cancer with no recurrence or metastasis.

All the patients were evaluated using the Hospital Anxiety and Depression Scale (HADS) and the Body Image Scale (BIS). No significant effect on anxiety and body image was found by the researchers. They, however, noted a statistical difference between the results of the HADS depression test at T0 (first evaluation) and T1 (second evaluation) intervals. Read full press release to find out more at:




This article by Dr. Fausto Meriggi et al. is published in Reviews on Recent Clinical Trials, Volume 13, Issue 4, 2018. To obtain the article, please visit:


Press Release | Fighting to Find Relief: A new study shows decrease in depression in cancer patients


A New Study Published by Bentham Science Shows Support Groups and Educational Resources Can Decrease Depression in Breast Cancer Patients


1 in 8 women in the US will be diagnosed with breast cancer in their lifetime.

In 2018 alone, an estimated 266,120 new cases of breast cancer were diagnosed nationwide. As the numbers of new cases grow, the support network of women who suffer from breast cancer grows. In their ever-increasing numbers, the many women diagnosed with this disease face an arduous physical and emotional journey on their road to recovery, and along the way, many suffer from depression, anxiety, and body image issues.

Regardless of the prevalence of body image issues, anxiety, and depression in women who are suffering from breast cancer, there aren’t a lot of resources available for those afflicted. A recent study suggests it’s time to right that wrong. The study, published by Bentham Science, focused on Dr. Fausto Meriggi and his team at Fondazione Poliambulanza di Brescia who studied the effects of psychotherapeutic and educational groups on depression, anxiety, and body image issues among women suffering from breast cancer.


This study was published in Reviews on Recent Clinical Trials, a journal published by Bentham Science.  Bentham Science continues their work in the Middle East and North Africa, bringing education materials and increased accessibility to the region.


Read full press release to find out more at:



Prof Ludovico.jpg


Prof. Ludovico Abenavoli


Editor-in-Chief: Reviews on Recent Clinical Trials

University Magna Graecia



Da-Yong Lu.jpg

Contributed Article: Drug Combination in Clinical Cancer Treatments”



Reviews on Recent Clinical Trials Volume 13, Issue 1

Central Nervous System Agents in Medicinal Chemistry Volume 18, Issue 1

Drug Delivery Letters Volume 8, Issue 1

Current Nanoscience Volume 14, Issue 2

Current Nanomedicine Volume 8, Issue 1

Current Gene Therapy Volume 17, Issue 5

Nanoscience & Nanotechnology-Asia Volume 8, Issue 1

Adolescent Psychiatry Volume 7, Issue 2


EDITOR’S CHOICE – Neonatal Abstinence Syndrome Management – Reviews on Recent Clinical Trials

Journal: Reviews on Recent Clinical Trials

Author(s): Matthew Grossman*, Carl Seashore, Alison Volpe Holmes.


Background: The evaluation and management of infants with neonatal abstinence syndrome (NAS), the constellation of opioid withdrawal specific to newborns, have received renewed attention over the past decade during a new epidemic of opioid use, misuse, abuse, and dependence. Infants with NAS often endure long and costly hospital stays.

Objective: We aim to review recent literature on the management and outcomes of infants with, and at risk for, opioid withdrawal.

Methods: We reviewed articles indexed in PubMed over the past 5 years that examined interventions and/or outcomes related to the management of infants with NAS. Thirty-seven studies were included in our review comprising 8 categories: 1) identification of infants at risk for NAS, 2) prenatal factors, 3) evaluation of signs and symptoms, 4) non-pharmacologic care, including rooming-in and breastfeeding, 5) standardization of traditional protocols, 6) pharmacologic management, 7) alternative treatment approaches, and 8) long-term outcomes.

Results: Non-pharmacologic interventions, standardization of traditional protocols, and alternative treatment approaches were all associated with improved outcomes. Lengths of stay were generally lowest in the studies of non-pharmacologic interventions. Patients exposed to buprenorphine in utero tended to have better short-term outcomes than those exposed to methadone. Longer-term outcomes for infants with NAS appear to be worse than those of control groups.

Conclusion: The current epidemic necessitates both continued research, and the application of new evidence-based practices in the assessment and treatment of newborns exposed to opioids in utero. Projects focused on non-pharmacologic interventions appear to hold the most promise.

To access the article, please visit:



Drug Delivery Letters 7-3

Mini-Reviews in Medicinal Chemistry 17-17

Mini-Reviews in Medicinal Chemistry 17-18

Medicinal Chemistry 13-8  rM

Reviews on Recent Clinical Trials 12-3

Reviews on Recent Clinical Trials 12-4

Cardiovascular & Hematological Agents in Medicinal Chemistry 15-1

Current Analytical Chemistry 13-6

Recent Advances in Electrical & Electronic Engineering 10-3

Current Radiopharmaceuticals 10-3


Testimonial by Da-Yong Lu!

Da-Yong Lu

Contributed Article: “Drug Combination In Clinical Cancer Treatments

Highlighted Article – Evaluation of Salivary Melatonin Levels in HIV- Positive Patients – Reviews on Recent Clinical Trials

RRCT-Articles_12-4-Fatemeh Ahmadi-Motamayel

Most Accessed Article – Neoadjuvant Therapy for HER2-positive Breast Cancer – Reviews on Recent Clinical Trials

Journal: Reviews on Recent Clinical Trials

Author(s): Rachel Wuerstlein, Nadia Harbeck.

Graphical Abstract:



In HER2-positive early breast cancer, neoadjuvant treatment with a combination of sequential chemotherapy and HER2-targeted therapy is currently the standard of care. This is followed by breast surgery, radiotherapy (if indicated), completion of 12 months of HER2-directed therapy, and – depending on the tumor biology – endocrine adjuvant therapy, and ultimately follow up.

10-year survival rates in the HER2-positive subgroup of breast cancer do reach now more than 75% with the introduction of first adjvuant and later neoadjuvant HER2-targeted therapies over the last 15 years. The neoadjvuant setting helps to downstage locally advanced tumors, to provide early information of tumor response, to assess the efficacy of new therapies in vivo, to reduce treatment duration, and to introduce new targeted therapies into the clinical routine. It also allows enrolling fewer patients into clinical trials in order to reach adequate effects in clinical outcome.

The neoadjuvant approach and our interest in this setting are based on pCR (pathological complete response) and its translation into better long-term outcome. In recent trials, we have reached more than 60% pCR with a subsequent improvement of DFS and hopefully OS. Therefore, chemotherapy schedules and new HER2-targeted agents such as lapatinib, pertuzumab, and T-DM1 have been introduced into the neoadjuvant setting. To balance over- and undertreatment, current trials include personalized concepts and assess new biomarkers and tumorbiological factors. We have learned for example to differentiate between HR (hormone receptor)-positive and -negative tumors in the HER2-positive population. Depending on pCR or non-pCR after neoadjuvant treatment, the adjuvant therapy may be adjusted. This concept of post-neo-adjuvant trials is now entering the field of strategies in the neoadjuvant setting for HER2-positive non-metastatic primary breast cancer.
The 2017 standard of care in the neoadjuvant setting according to national and international guidelines combines a taxane-containing chemotherapy with a dual blockade of trastuzumab and pertuzumab.
This review will point out current trials and their strategies to continue improving outcome and reduce morbidity as well as mortality in HER2-positive early breast cancer.
%d bloggers like this: